Format

Send to

Choose Destination
Nephrol Dial Transplant. 2014 Aug;29(8):1487-93. doi: 10.1093/ndt/gft538. Epub 2014 Feb 9.

Mesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion.

Author information

1
Divisions of Nephrology and Transplantation, University of Liege CHU (ULg CHU), Liege, Belgium.
2
Abdominal Surgery and Transplantation, University of Liege CHU (ULg CHU), Liege, Belgium Laboratories of Cardiovascular Sciences, University of Liege, Liege, Belgium.
3
Laboratory of Cell and Gene Therapy, University of Liege CHU (ULg CHU), Liege, Belgium.
4
Laboratory of Cell and Gene Therapy, University of Liege CHU (ULg CHU), Liege, Belgium Hematology, Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA), University of Liege, Liege, Belgium.
5
Divisions of Nephrology and Transplantation, University of Liege CHU (ULg CHU), Liege, Belgium Laboratories of Cardiovascular Sciences, University of Liege, Liege, Belgium.

Abstract

Acute kidney injury (AKI) represents a worldwide public health issue of increasing incidence, with a significant morbi-mortality. AKI treatment mostly relies on supportive manoeuvres in the absence of specific target-oriented therapy. The pathophysiology of AKI commonly involves ischaemia/reperfusion (I/R) events, which cause both immune and metabolic consequences in renal tissue. Similarly, at the time of kidney transplantation (KT), I/R is an unavoidable event which contributes to early graft dysfunction and enhanced graft immunogenicity. Mesenchymal stromal cells (MSCs) represent a heterogeneous population of adult, fibroblast-like multi-potent cells characterized by their ability to differentiate into tissues of mesodermal lineages. Because MSC have demonstrated immunomodulatory, anti-inflammatory and tissue repair properties, MSC administration at the time of I/R and/or at later times has been hypothesized to attenuate AKI severity and to accelerate the regeneration process. Furthermore, MSC in KT could help prevent both I/R injury and acute rejection, thereby increasing graft function and survival. In this review, summarizing the encouraging observations in animal models and in pilot clinical trials, we outline the benefit of MSC therapy in AKI and KT, and envisage their putative role in renal ischaemic conditioning.

KEYWORDS:

acute kidney injury; ischaemia/reperfusion; ischaemic conditioning; kidney transplantation; mesenchymal stromal cells

PMID:
24516234
DOI:
10.1093/ndt/gft538
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for ORBi (University of Liege)
Loading ...
Support Center